{"id":4545,"date":"2021-06-17T15:30:07","date_gmt":"2021-06-17T12:30:07","guid":{"rendered":"https:\/\/www.klimik.org.tr\/koronavirus\/?p=4545"},"modified":"2021-07-16T11:49:37","modified_gmt":"2021-07-16T08:49:37","slug":"covid-19-asisi-olmak-pandeminin-kontrol-altina-alinmasinda-nicin-onemlidir","status":"publish","type":"post","link":"https:\/\/www.klimik.org.tr\/koronavirus\/covid-19-asisi-olmak-pandeminin-kontrol-altina-alinmasinda-nicin-onemlidir\/","title":{"rendered":"COVID-19 A\u015f\u0131lar\u0131yla \u0130lgili \u00c7ok Sorulan Sorular ve Yan\u0131tlar\u0131 \/ Klimik Derne\u011fi"},"content":{"rendered":"
\n
\n <\/div>\n\n
\n \n
\n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n COVID-19 a\u015f\u0131s\u0131 olmak pandeminin kontrol alt\u0131na al\u0131nmas\u0131nda ni\u00e7in \u00f6nemlidir?<\/span>\n <\/div>\n
\n

COVID pandemisini kontrol alt\u0131na alabilmenin tek yolu hastal\u0131\u011f\u0131n bula\u015fmas\u0131n\u0131 azaltmakt\u0131r. Vir\u00fcs insanlar aras\u0131nda yay\u0131ld\u0131k\u00e7a de\u011fi\u015fime u\u011framakta ve daha bula\u015f\u0131c\u0131, daha a\u011f\u0131r hastal\u0131k yapan ve a\u015f\u0131lar\u0131n etkisine daha dayan\u0131kl\u0131 varyantlar ortaya \u00e7\u0131kmaktad\u0131r. A\u015f\u0131, ki\u015fileri korumak ve pandemiyi durdurman\u0131n yan\u0131 s\u0131ra varyant geli\u015fmesini engellemek i\u00e7in de en etkili y\u00f6ntemdir.<\/p>\n

Bula\u015f\u0131c\u0131 hastal\u0131klarda, bir toplumda hastal\u0131\u011fa kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k kazanm\u0131\u015f bireylerin say\u0131s\u0131 belirli bir oran\u0131n \u00fczerinde olursa o hastal\u0131\u011f\u0131n toplumda yay\u0131lmas\u0131 belirgin \u015fekilde azal\u0131r. Pandeminin ba\u015f\u0131ndan itibaren s\u0131kl\u0131kla kullan\u0131lan \u201cs\u00fcr\u00fc ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131-herd immunity<\/em>\u201d ifadesi, toplum ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131n\u0131 ifade etmektedir. Her bula\u015f\u0131c\u0131 hastal\u0131k i\u00e7in hastal\u0131\u011f\u0131n yay\u0131l\u0131m\u0131n\u0131 durdurabilmek amac\u0131yla gereken toplum ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 oran\u0131 de\u011fi\u015fmektedir. Hastal\u0131k etkeninin bula\u015fma h\u0131z\u0131na ve a\u015f\u0131lar\u0131n etkinlik oranlar\u0131na g\u00f6re de\u011fi\u015fmekle birlikte salg\u0131n\u0131n kontrol alt\u0131na al\u0131nabilmesi i\u00e7in T\u00fcrkiye\u2019de yakla\u015f\u0131k 60-70 milyon ki\u015finin a\u015f\u0131 olmas\u0131 gerekmektedir. Daha bula\u015f\u0131c\u0131 varyantlar ortaya \u00e7\u0131karsa bu say\u0131 artacakt\u0131r.<\/p>\n

K\u0131saca \u00f6zetlemek gerekirse, salg\u0131n\u0131n yay\u0131l\u0131m\u0131n\u0131 durdurmak i\u00e7in ula\u015f\u0131lmas\u0131 gereken toplum ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 oran\u0131na sadece a\u015f\u0131lanma yoluyla g\u00fcvenli bir \u015fekilde ula\u015f\u0131labilir.<\/p>\n <\/div>\n \n

\n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Ka\u00e7 t\u00fcr COVID-19 a\u015f\u0131s\u0131 vard\u0131r? <\/span>\n <\/div>\n
\n

COVID hastal\u0131\u011f\u0131 i\u00e7in be\u015f t\u00fcr a\u015f\u0131 geli\u015ftirilmi\u015ftir. Bu a\u015f\u0131lar\u0131n d\u00f6rd\u00fc bilinen y\u00f6ntemlerle geli\u015ftirilirken mRNA a\u015f\u0131lar\u0131 yeni bir teknoloji ile geli\u015ftirilmi\u015ftir.<\/p>\n

    \n
  • \u0130naktive vir\u00fcs a\u015f\u0131lar\u0131;<\/strong> hastal\u0131\u011fa neden olmayan ancak ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 olu\u015fturan etkisizle\u015ftirilmi\u015f vir\u00fcs i\u00e7eren a\u015f\u0131lard\u0131r. \u00dclkemizde uygulanmakta olan Sinovac\u2019\u0131n CoronaVac a\u015f\u0131s\u0131 ve her y\u0131l uygulanan grip (influenza) a\u015f\u0131lar\u0131 inaktif a\u015f\u0131lard\u0131r.<\/li>\n
  • Canl\u0131 aten\u00fce a\u015f\u0131lar;<\/strong> hastal\u0131\u011fa neden olmayan ancak ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 olu\u015fturan zay\u0131flat\u0131lm\u0131\u015f vir\u00fcs i\u00e7eren a\u015f\u0131lard\u0131r. K\u0131zam\u0131k, kabakulak, su \u00e7i\u00e7e\u011fi a\u015f\u0131lar\u0131 da canl\u0131 aten\u00fce vir\u00fcs a\u015f\u0131lar\u0131d\u0131r. Hen\u00fcz d\u00fcnyada kullan\u0131ma girmi\u015f canl\u0131 aten\u00fce COVID-19 a\u015f\u0131s\u0131 bulunmamaktad\u0131r.<\/li>\n
  • Protein subunit a\u015f\u0131lar\u0131;<\/strong> vir\u00fcs\u00fcn yap\u0131s\u0131n\u0131 taklit eden protein par\u00e7alar\u0131n\u0131 kullanan protein bazl\u0131 a\u015f\u0131lard\u0131r. Novovax \u00ae a\u015f\u0131s\u0131 bu t\u00fcden a\u015f\u0131d\u0131r.<\/li>\n
  • Viral vekt\u00f6r a\u015f\u0131lar\u0131;<\/strong> SARS-CoV-2 vir\u00fcs\u00fcn\u00fcn RNA par\u00e7ac\u0131klar\u0131n\u0131 ta\u015f\u0131yan hastal\u0131k yap\u0131c\u0131 etkisi olmayan vir\u00fcslerin kullan\u0131ld\u0131\u011f\u0131 a\u015f\u0131lard\u0131r. Oxford-AstraZeneca a\u015f\u0131s\u0131, Sputnik V a\u015f\u0131s\u0131 bu t\u00fcrden a\u015f\u0131lard\u0131r.<\/li>\n
  • m-RNA a\u015f\u0131lar\u0131;<\/strong> protein \u00fcretmek i\u00e7in genetik olarak tasarlanm\u0131\u015f RNA par\u00e7ac\u0131klar\u0131n\u0131 kullanan yeni teknoloji \u00fcr\u00fcn\u00fc a\u015f\u0131lar\u0131d\u0131r. \u00dclkemizde uygulanmakta olan BioNTech a\u015f\u0131s\u0131 bu t\u00fcrden bir a\u015f\u0131d\u0131r.<\/li>\n<\/ul>\n

    2021 y\u0131l\u0131 Haziran ay\u0131 itibariyle d\u00fcnyada acil kullan\u0131m onay\u0131 ve ruhsat alm\u0131\u015f 11 a\u015f\u0131, kullan\u0131m onay\u0131 almak \u00fczere olan bir a\u015f\u0131 olmak \u00fczere toplam 12 adet a\u015f\u0131 bulunmaktad\u0131r.<\/p>\n

    Acil kullan\u0131m onay\u0131 veya ruhsat alan a\u015f\u0131lar; Pfizer\/BioNTech (ABD-Almanya-mRNA a\u015f\u0131s\u0131), Moderna (ABD-mRNA a\u015f\u0131s\u0131), Oxford-AstraZeneca (Birle\u015fik Krall\u0131k-Viral vekt\u00f6r a\u015f\u0131s\u0131), Johnson & Johnson (ABD-Viral vekt\u00f6r a\u015f\u0131s\u0131), Gameleya-Sputnik V (Rusya-Viral vekt\u00f6r a\u015f\u0131s\u0131), SinoPharm (\u00c7in-\u0130naktive vir\u00fcs a\u015f\u0131s\u0131), Sinopharm Wuhan (\u00c7in-\u0130naktif a\u015f\u0131), Cansino (\u00c7in-Viral vekt\u00f6r a\u015f\u0131s\u0131), Sinovac (\u00c7in-\u0130naktive vir\u00fcs a\u015f\u0131s\u0131), Bharat Bitech (Hindistan-\u0130naktive vir\u00fcs a\u015f\u0131s\u0131), Vector Institute (Rusya-Protein subunit a\u015f\u0131s\u0131) olarak s\u0131ralanabilir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Acil kullan\u0131m onay\u0131 \u00e7ok h\u0131zl\u0131 verilmedi mi? A\u015f\u0131lar\u0131n g\u00fcvenli olduklar\u0131 kesin bilgi mi?<\/span>\n <\/div>\n
    \n

    COVID-19 a\u015f\u0131lar\u0131n\u0131n h\u0131zl\u0131 geli\u015ftirilmi\u015f olmalar\u0131 ve kullan\u0131lmaya ba\u015flanmalar\u0131 a\u015f\u0131lar\u0131n g\u00fcvensiz oldu\u011fu anlam\u0131na gelmez. Bilimsel teknolojik ilerlemenin geldi\u011fi nokta, teknolojik altyap\u0131n\u0131n haz\u0131r olmas\u0131, salg\u0131n\u0131n en ba\u015f\u0131nda vir\u00fcs\u00fcn genetik haritas\u0131n\u0131n \u00e7\u0131kart\u0131lm\u0131\u015f olmas\u0131, ulusal ve uluslararas\u0131 kurulu\u015flar\u0131n b\u00fcy\u00fck deste\u011fi, a\u015f\u0131lar\u0131n bu kadar h\u0131zl\u0131 geli\u015ftirilmesini sa\u011flam\u0131\u015ft\u0131r. \u00d6rne\u011fin mRNA a\u015f\u0131lar\u0131 \u00fczerinde y\u00fczlerce bilim insan\u0131 30 y\u0131ldan uzun bir s\u00fcredir \u00e7al\u0131\u015fmakta oldu\u011fu i\u00e7in h\u0131zla \u00fcretilebilmi\u015flerdir. A\u015f\u0131 sonras\u0131 ciddi yan etkiler genellikle ilk 2 ay i\u00e7erisinde ortaya \u00e7\u0131kt\u0131\u011f\u0131ndan acil kullan\u0131m onay\u0131 veren kurulu\u015flar \u00e7al\u0131\u015fmalarda 2 ay sonunda yan etki g\u00f6r\u00fclmemesini yeterli kabul etmi\u015flerdir. Bug\u00fcne kadar 6 aydan uzun bir s\u00fcre i\u00e7inde farkl\u0131 a\u015f\u0131lardan toplam 2,5 milyar doz uygulanm\u0131\u015f ve sonu\u00e7lar\u0131n g\u00f6zlenme \u015fans\u0131 olmu\u015ftur. Hem Sinovac\u00ae hem BioNTech\u00ae d\u00fcnya genelinde g\u00fcvenle uygulanmaya devam etmektedir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n COVID-19 a\u015f\u0131lar\u0131n\u0131n yan etkisi yok mu?<\/span>\n <\/div>\n
    \n

    T\u00fcm a\u015f\u0131larda oldu\u011fu gibi COVID-19 a\u015f\u0131lar\u0131n\u0131n da yan etkileri olabilmektedir. S\u0131k g\u00f6r\u00fclen yan etkiler a\u015f\u0131 yerinde a\u011fr\u0131, ate\u015f, halsizlik, ba\u015f a\u011fr\u0131s\u0131, kas a\u011fr\u0131s\u0131, ishal gibi yan etkilerdir. Bu yan etkiler, a\u015f\u0131 ile verilen antijene kar\u015f\u0131 v\u00fccudumuzun yan\u0131t vermesi nedeniyle ortaya \u00e7\u0131kar. Genellikle k\u0131sa (1-3 g\u00fcn) s\u00fcrer ve \u00e7o\u011funlukla g\u00fcnl\u00fck ya\u015fant\u0131m\u0131z\u0131 engellemeyecek kadar hafiftirler. \u0130ki dozda uygulanan a\u015f\u0131larda ikinci dozdan sonra yan etkiler biraz daha s\u0131k g\u00f6r\u00fclebilir. \u015eikayetler a\u011fr\u0131 kesici, ate\u015f d\u00fc\u015f\u00fcr\u00fcc\u00fc ile azalt\u0131labilir. 3 g\u00fcnden uzun s\u00fcren yan etkilerde doktora ba\u015fvurman\u0131zda fayda olacakt\u0131r. Nadir g\u00f6r\u00fclen yan etkiler %1\u2019den daha az s\u0131kl\u0131kta kar\u015f\u0131m\u0131za \u00e7\u0131kar. Alerji bunlar\u0131n ba\u015f\u0131nda gelir. \u00c7o\u011fu alerjik yan etki \u00f6nemsizdir, \u00e7ok nadiren ciddi alerji geli\u015febilir. Ciddi alerji a\u015f\u0131dan sonraki ilk dakikalarda ortaya \u00e7\u0131kaca\u011f\u0131 i\u00e7in a\u015f\u0131lanan ki\u015filerin sa\u011fl\u0131k kurulu\u015funu 15-30 dakikadan \u00f6nce terk etmemesi gerekir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Hangi COVID-19 a\u015f\u0131s\u0131n\u0131 olmal\u0131y\u0131z?<\/span>\n <\/div>\n
    \n

    Bug\u00fcne kadar geli\u015ftirilen ve acil kullan\u0131m onay\u0131 alan t\u00fcm COVID-19 a\u015f\u0131lar\u0131 g\u00fcvenlidir. Etkileri ve yan etkileri birbirlerine k\u0131yasla farkl\u0131l\u0131k g\u00f6stermekte ise de hepsi D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc\u2019n\u00fcn etkililik ve g\u00fcvenlik kriterlerini kar\u015f\u0131lamaktad\u0131r. Bu nedenle, herhangi bir a\u015f\u0131y\u0131 \u00f6zellikle beklemeksizin ilk temin edilecek a\u015f\u0131y\u0131 olman\u0131z \u00f6nerilir.\u00a0 D\u00fcnya genelinde uygulanmakta olan a\u015f\u0131lar i\u00e7erisinde varyantlara y\u00fcksek etkisi ve \u00e7ok say\u0131da ki\u015fiye uygulanm\u0131\u015f olmas\u0131ndan kaynaklanan bilimsel veri zenginli\u011fi ile BioNTech\u00ae \u00f6ne \u00e7\u0131kmaktad\u0131r.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Daha \u00f6nce COVID\u2019e benzer \u015fikayetleri olan ancak PCR ile pozitiflik tespit edilmeyen ki\u015filer \u015fimdi a\u015f\u0131lans\u0131nlar m\u0131?<\/span>\n <\/div>\n
    \n

    Daha \u00f6nce PCR testi ile COVID-19 ge\u00e7irdi\u011fi kan\u0131tlanmayan herkes, bir d\u00f6nem COVID-19\u2019a benzer \u015fikayetler ya\u015fam\u0131\u015f olsalar bile a\u015f\u0131lanmal\u0131d\u0131r. A\u015f\u0131lar\u0131n COVID-19 ge\u00e7irmi\u015f olan ki\u015filerde farkl\u0131 yan etkileri de olmad\u0131\u011f\u0131ndan g\u00fcvenli bir \u015fekilde a\u015f\u0131lanabilirler.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n COVID-19 a\u015f\u0131s\u0131ndan sonra testlerim pozitifle\u015fir mi? Antikor testlerime bakt\u0131rmal\u0131 m\u0131y\u0131m?<\/span>\n <\/div>\n
    \n

    COVID-19 a\u015f\u0131s\u0131 sonras\u0131nda PCR veya antijen testleri pozitifle\u015fmez. Antikor testlerinde pozitifle\u015fme olabilir. Ancak antikor testleri a\u015f\u0131n\u0131n i\u015fe yaray\u0131p yaramad\u0131\u011f\u0131n\u0131 g\u00f6stermek i\u00e7in kullan\u0131lmazlar. A\u015f\u0131dan sonra antikorlar\u0131n\u0131za bakt\u0131rman\u0131za gerek yoktur. A\u015f\u0131lar\u0131n sa\u011flad\u0131\u011f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k sadece antikorlara ba\u011fl\u0131 de\u011fildir. Rutin testlerle \u00f6l\u00e7emedi\u011fimiz h\u00fccre ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 ve salg\u0131lar\u0131m\u0131zda olu\u015fan antikorlar korunmada \u00e7ok \u00f6nemli rol oynarlar.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n COVID-19 a\u015f\u0131s\u0131ndan \u00f6nce antikorlar\u0131ma bakt\u0131rmal\u0131 m\u0131y\u0131m?<\/span>\n <\/div>\n
    \n

    Hay\u0131r. Antikorlar\u0131n miktar\u0131 koruyuculu\u011fun derecesi hakk\u0131nda bilgi vermedi\u011fi gibi testlerden kaynaklanan nedenlerle yalanc\u0131 olarak pozitif sonu\u00e7 da \u00e7\u0131kabilmektedir. Bu nedenle a\u015f\u0131 olmak veya olmamak karar\u0131 i\u00e7in antikorlar\u0131n\u0131za bakt\u0131rman\u0131za gerek yoktur.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n A\u015f\u0131 olmak COVID-19\u2019a neden olur mu?<\/span>\n <\/div>\n
    \n

    Hay\u0131r. Acil kullan\u0131m onay\u0131 alm\u0131\u015f a\u015f\u0131lar ba\u011f\u0131\u015f\u0131kl\u0131k sistemimize vir\u00fcs\u00fc tan\u0131tmak i\u00e7in farkl\u0131 teknolojileri kullan\u0131rlar ancak hi\u00e7birinin i\u00e7erisinde canl\u0131 vir\u00fcs bulunmamaktad\u0131r.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Tek doz a\u015f\u0131 COVID-19\u2019dan korur mu?<\/span>\n <\/div>\n
    \n

    \u0130ki dozda uygulanmas\u0131 gereken a\u015f\u0131lar\u0131n birinci dozundan sonra geli\u015fen koruma yeterli miktarda de\u011fildir. Bu y\u00fczden ancak iki dozu tamamlad\u0131ktan ve ikinci dozun \u00fczerinden 14 g\u00fcn ge\u00e7tikten sonra a\u015f\u0131n\u0131n koruyuculu\u011funun tam olarak ba\u015flad\u0131\u011f\u0131n\u0131 unutmamak gerekir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n \u0130kinci doz a\u015f\u0131y\u0131 farkl\u0131 bir a\u015f\u0131 olabilir miyim?<\/span>\n <\/div>\n
    \n

    \u0130ki doz \u015feklinde uygulanan a\u015f\u0131larda (\u00fclkemizdeki her iki a\u015f\u0131 da b\u00f6yledir) ilk a\u015f\u0131lama \u015femas\u0131n\u0131n (iki dozun) ayn\u0131 a\u015f\u0131 ile yap\u0131lmas\u0131 gerekir. \u0130ki doz a\u015f\u0131y\u0131 ayn\u0131 a\u015f\u0131yla olduktan sonra hat\u0131rlatma (rapel) dozlar\u0131n\u0131n farkl\u0131 t\u00fcrde bir a\u015f\u0131yla yap\u0131lmas\u0131 konusunda \u00e7al\u0131\u015fmalar devam etmektedir, ilk veriler farkl\u0131 a\u015f\u0131 t\u00fcrleriyle yap\u0131lan a\u015f\u0131lamalar\u0131n etkili ve g\u00fcvenli olabilece\u011fini d\u00fc\u015f\u00fcnd\u00fcrmektedir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n \u0130lk doz a\u015f\u0131dan sonra yan etki ortaya \u00e7\u0131karsa ikinci doz a\u015f\u0131y\u0131 yine de olmal\u0131 m\u0131y\u0131m?<\/span>\n <\/div>\n
    \n

    \u0130lk dozdan sonra ciddi yan etki geli\u015fmedi\u011fi s\u00fcrece ikinci doz a\u015f\u0131n\u0131z\u0131 olman\u0131zda sak\u0131nca yoktur. \u0130lk dozla ciddi yan etki geli\u015fti ise ikinci doz a\u015f\u0131n\u0131n uygulanmas\u0131 karar\u0131n\u0131 hekiminizle g\u00f6r\u00fc\u015ft\u00fckten sonra vermelisiniz. Pek \u00e7ok durumda ikinci doz yine de uygulabilecektir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n A\u015f\u0131lanm\u0131\u015f olsak da COVID-19 ge\u00e7irme olas\u0131l\u0131\u011f\u0131 var m\u0131? <\/span>\n <\/div>\n
    \n

    Evet. Mevcut a\u015f\u0131lar belirtili hastal\u0131\u011fa kar\u015f\u0131 etkili bir koruma sa\u011flamakla birlikte vir\u00fcs\u00fcn solunum h\u00fccrelerinde \u00e7o\u011falmas\u0131n\u0131 engelleme yetene\u011fi a\u015f\u0131dan a\u015f\u0131ya farkl\u0131l\u0131k g\u00f6sterir. A\u015f\u0131lanan ki\u015filere vir\u00fcs bula\u015fabilir ve hi\u00e7 hastalanmadan da bula\u015ft\u0131r\u0131c\u0131 olabilirler. \u00c7ok d\u00fc\u015f\u00fck olas\u0131l\u0131kla kendileri de hastalanabilirler. Bu nedenle a\u015f\u0131lanm\u0131\u015f ki\u015filerin ki\u015fisel korunma \u00f6nlemlerine salg\u0131n kontrol alt\u0131na al\u0131nana kadar uymalar\u0131 gereklidir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Di\u011fer a\u015f\u0131larla COVID-19 a\u015f\u0131lar\u0131 aras\u0131nda belirli bir s\u00fcre olmas\u0131 gerekir mi?<\/span>\n <\/div>\n
    \n

    Hem Sinovac\u00ae hem BioNTech\u00ae di\u011fer herhangi bir a\u015f\u0131dan \u00f6nce, sonra ya da e\u015f zamanl\u0131 olarak g\u00fcvenle uygulanabilir. Ancak bir yan etki geli\u015fmesi durumunda hangi a\u015f\u0131ya ba\u011fl\u0131 oldu\u011funun anla\u015f\u0131lmas\u0131 ve kay\u0131tlar\u0131n do\u011fru tutulabilmesi i\u00e7in m\u00fcmk\u00fcnse di\u011fer a\u015f\u0131 ile arada 14 g\u00fcn s\u00fcre b\u0131rak\u0131lmal\u0131d\u0131r.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Halen COVID-19 hastas\u0131yla temas\u0131m nedeniyle riskli durumday\u0131m. A\u015f\u0131lanabilir miyim?<\/span>\n <\/div>\n
    \n

    On d\u00f6rt g\u00fcnden k\u0131sa bir s\u00fcre \u00f6nce COVID-19 hastas\u0131yla maske, mesafe ve havaland\u0131rma ko\u015fullar\u0131na uymayan bir bi\u00e7imde temas\u0131 olan ki\u015filerin a\u015f\u0131lanmak i\u00e7in karantina s\u00fcrelerinin dolmas\u0131n\u0131 beklemeleri \u00f6nerilmektedir.\u00a0 Bu \u00f6nerinin nedeni bu ki\u015filere yap\u0131lacak olan a\u015f\u0131n\u0131n zarar\u0131ndan ziyade, a\u015f\u0131n\u0131n bu durumda koruma etkisinin olmamas\u0131ndan kaynaklanmaktad\u0131r.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n A\u015f\u0131 k\u0131s\u0131rl\u0131k yapar m\u0131? \u0130leride sahip olaca\u011f\u0131m \u00e7ocukta olumsuz etki yapar m\u0131?<\/span>\n <\/div>\n
    \n

    A\u015f\u0131lar k\u0131s\u0131rl\u0131k yapmaz. A\u015f\u0131dan sonraki aylarda, y\u0131llarda ger\u00e7ekle\u015fecek gebeliklerden do\u011facak bebekler \u00fczerinde hi\u00e7bir a\u015f\u0131n\u0131n olumsuz etkisinin olmas\u0131 beklenmez. A\u015f\u0131 hamilelere yap\u0131ld\u0131\u011f\u0131nda bile bebe\u011fe zarar vermemektedir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Gebeler veya gebe kalmak isteyenler a\u015f\u0131lans\u0131nlar m\u0131? Hangi a\u015f\u0131y\u0131 ne zaman olsunlar?<\/span>\n <\/div>\n
    \n

    Gebe veya gebe kalmak isteyenler COVID-19\u2019a kar\u015f\u0131 a\u015f\u0131lanmal\u0131d\u0131r. Hi\u00e7bir a\u015f\u0131n\u0131n gelecekte ger\u00e7ekle\u015fecek bir gebelik \u00fczerinde olumsuz etkisi yoktur.<\/p>\n

    COVID-19 a\u015f\u0131lar\u0131 gebeli\u011fin ba\u015f\u0131ndan itibaren uygulanabilir. Ancak ilk \u00fc\u00e7 ayda farkl\u0131 nedenlere ba\u011fl\u0131 d\u00fc\u015f\u00fckler s\u0131kt\u0131r ve bu d\u00f6nemde ger\u00e7ekle\u015febilecek bir bebek kayb\u0131n\u0131n a\u015f\u0131yla ili\u015fkilendirilmemesi i\u00e7in a\u015f\u0131lar\u0131n gebelikten \u00f6nce veya \u00fc\u00e7\u00fcnc\u00fc aydan sonra yap\u0131lmas\u0131 tercih edilmektedir. Mevcut COVID-19 a\u015f\u0131lar\u0131 aras\u0131nda gebelikte kullan\u0131ma dair en fazla veri BioNTech\u00ae a\u015f\u0131s\u0131na ait olup g\u00fcvenli oldu\u011fu g\u00f6sterilmi\u015ftir. 3. aydan sonra uygulanabilir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Emziren anneler a\u015f\u0131 olabilir mi?<\/span>\n <\/div>\n
    \n

    Evet. Emziren anneler de COVID-19\u2019a kar\u015f\u0131 a\u015f\u0131lanmal\u0131d\u0131r. Mevcut COVID-19 a\u015f\u0131lar\u0131 anne s\u00fct\u00fc alan bebeklerde herhangi bir yan etkiye neden olmaz.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Yumurta alerjisi olanlar hangi a\u015f\u0131y\u0131 olmal\u0131?<\/span>\n <\/div>\n
    \n

    Grip a\u015f\u0131lar\u0131ndan farkl\u0131 olarak mevcut COVID-19 a\u015f\u0131lar\u0131n\u0131n hi\u00e7biri yumurtada \u00fcretilmemektedir. Yumurtaya kar\u015f\u0131 alerjisi olanlar di\u011fer alerjik b\u00fcnyeli ki\u015filer gibi Sinovac\u00ae veya BioNTech\u00ae a\u015f\u0131s\u0131n\u0131 olabilirler.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Kanser hastalar\u0131 hangi a\u015f\u0131y\u0131 olsunlar? Ne zaman olsunlar?<\/span>\n <\/div>\n
    \n

    Hem Sinovac\u00ae hem BioNTech\u00ae kanser hastalar\u0131nda g\u00fcvenle uygulanabilir. Ancak BioNTech\u00ae a\u015f\u0131s\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k sistemi zay\u0131flam\u0131\u015f ki\u015filerde daha y\u00fcksek oranda koruma sa\u011flad\u0131\u011f\u0131 i\u00e7in tercih edilmelidir. \u0130deal zamanlama kemoterapi ba\u015flamadan \u00f6nce a\u015f\u0131laman\u0131n yap\u0131lmas\u0131d\u0131r. Ancak kemoterapinin geciktirilemeyece\u011fi durumlarda kemoterapiden birka\u00e7 g\u00fcn \u00f6nce a\u015f\u0131 yap\u0131labilir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Ba\u011f\u0131\u015f\u0131kl\u0131k sistemi zay\u0131f olan ki\u015filer hangi a\u015f\u0131y\u0131 olsunlar?<\/span>\n <\/div>\n
    \n

    Hem Sinovac\u00ae hem BioNTech\u00ae ba\u011f\u0131\u015f\u0131kl\u0131k sistemi zay\u0131flam\u0131\u015f hastalarda g\u00fcvenle uygulanabilir. Ancak BioNTech\u00ae a\u015f\u0131s\u0131, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi zay\u0131flam\u0131\u015f ki\u015filerde daha y\u00fcksek oranda koruma sa\u011flad\u0131\u011f\u0131 i\u00e7in, tercih edilmelidir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Multiple Skleroz veya ba\u015fka sinir hastal\u0131\u011f\u0131 olanlar a\u015f\u0131 olabilir mi?<\/span>\n <\/div>\n
    \n

    Evet. COVID-19 a\u015f\u0131lar\u0131n\u0131n sinir sistemi \u00fczerinde olumsuz etkileri g\u00f6sterilmedi\u011fi gibi bu t\u00fcr hastal\u0131\u011f\u0131 olanlarda da g\u00fcvenle kullan\u0131lmaktad\u0131rlar. Tedavi alt\u0131ndaki hastalar\u0131n hangi a\u015f\u0131y\u0131 ne zaman olmalar\u0131 gerekti\u011fini kendilerini takip eden doktorlar\u0131na sormalar\u0131 \u00f6nerilir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n HIV pozitif bireyler a\u015f\u0131lanabilir mi?<\/span>\n <\/div>\n
    \n

    HIV pozitif bireylerin COVID-19\u2019a kar\u015f\u0131 a\u015f\u0131lanmas\u0131na engel bir durum\u00a0 bulunmamaktad\u0131r. Tersine ba\u011f\u0131\u015f\u0131kl\u0131k sistemi bask\u0131lanm\u0131\u015f oldu\u011fu i\u00e7in COVID-19 hastal\u0131\u011f\u0131n\u0131 a\u011f\u0131r ge\u00e7irebilirler bu y\u00fczden a\u015f\u0131lanmalar\u0131 gerekir. Ancak, HIV infeksiyonu nedeniyle hen\u00fcz yeni tedavi ba\u015flanm\u0131\u015f olup kanda viral y\u00fck\u00fc y\u00fcksek ve\/veya CD4+ T h\u00fccre say\u0131s\u0131 <200\/mm3 <\/sup>olan bireylerde a\u015f\u0131 yan\u0131t\u0131 sa\u011fl\u0131kl\u0131 pop\u00fclasyona g\u00f6re daha az olabilir. Bu ki\u015filerde daha g\u00fc\u00e7l\u00fc koruma sa\u011flad\u0131\u011f\u0131 i\u00e7in BioNTech\u00ae a\u015f\u0131s\u0131 tercih edilmelidir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Romatizmal veya otoimm\u00fcn hastal\u0131\u011f\u0131 olanlar BioNTech\u00ae a\u015f\u0131s\u0131 olabilir mi?<\/span>\n <\/div>\n
    \n

    BioNTech\u00ae a\u015f\u0131s\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k sistemini g\u00fc\u00e7l\u00fc bir \u015fekilde uyarmakta ve bu sayede y\u00fcksek oranda ve nispeten uzun s\u00fcreli ba\u011f\u0131\u015f\u0131kl\u0131k sa\u011flamaktad\u0131r. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemini g\u00fc\u00e7l\u00fc uyarmas\u0131, romatizmal hastal\u0131\u011f\u0131 olan baz\u0131 ki\u015filerde hastal\u0131k belirtilerinde bir miktar art\u0131\u015fa yol a\u00e7abilir. Ancak bu art\u0131\u015f ge\u00e7ici oldu\u011fu gibi hastal\u0131\u011f\u0131n uzun s\u00fcreli seyrini de etkilememektedir. Bu nedenle \u00f6zellikle ba\u011f\u0131\u015f\u0131kl\u0131k sistemini bask\u0131layan ila\u00e7larla tedavi almakta olan hastalar\u0131n BioNTech\u00ae a\u015f\u0131s\u0131 olmas\u0131 \u00f6nerilir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Alerjik b\u00fcnyesi olanlar BioNTech\u00ae olabilir mi?<\/span>\n <\/div>\n
    \n

    Alerjik b\u00fcnyesi olanlar, hatta daha \u00f6nce herhangi bir maddeye veya ilaca (Penisilin gibi) kar\u015f\u0131 ciddi alerjisi geli\u015fmi\u015f ki\u015filer sa\u011fl\u0131k kurulu\u015funda g\u00f6zetim alt\u0131nda olmak kayd\u0131yla BioNTech\u00ae a\u015f\u0131s\u0131 olabilirler. Alerjik yan\u0131t geli\u015fme s\u0131kl\u0131\u011f\u0131 BioNTech\u00ae a\u015f\u0131s\u0131nda biraz daha y\u00fcksek olmakla birlikte t\u00fcm a\u015f\u0131larda s\u00f6z konusu olabilir. A\u015f\u0131lara ba\u011fl\u0131 ciddi alerjik reaksiyonlar\u0131n b\u00fcy\u00fck \u00e7o\u011funlu\u011fu ilk dakikalarda ortaya \u00e7\u0131kt\u0131\u011f\u0131ndan a\u015f\u0131 olan ki\u015filer sa\u011fl\u0131k kurulu\u015funu 15-30 dakikadan \u00f6nce terk etmemelidir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n A\u015f\u0131lar\u0131n varyantlara etkisi farkl\u0131 m\u0131?<\/span>\n <\/div>\n
    \n

    D\u00fcnya genelinde yap\u0131lan \u00e7al\u0131\u015fmalarda hemen t\u00fcm a\u015f\u0131lar\u0131n varyantlara kar\u015f\u0131 azalm\u0131\u015f da olsa etkileri oldu\u011fu g\u00f6sterilmi\u015ftir. Mevcut a\u015f\u0131lar aras\u0131nda BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n varyantlara di\u011fer a\u015f\u0131lara k\u0131yasla biraz daha etkili oldu\u011funu g\u00f6steren yay\u0131nlar mevcuttur.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n A\u015f\u0131 oldu\u011fum g\u00fcn a\u011fr\u0131 kesici ila\u00e7 kullanabilir miyim?<\/span>\n <\/div>\n
    \n

    A\u015f\u0131 g\u00fcn\u00fc a\u011fr\u0131 kesici veya ate\u015f d\u00fc\u015f\u00fcr\u00fcc\u00fc olarak parasetamol i\u00e7eren ila\u00e7lar\u0131n kullan\u0131lmas\u0131 a\u015f\u0131n\u0131n etkisini azaltmaz. A\u015f\u0131ya ba\u011fl\u0131 kol a\u011fr\u0131s\u0131, k\u0131zar\u0131kl\u0131k \u015fi\u015flik gibi durumlar ortaya \u00e7\u0131kmas\u0131 halinde parasetamol i\u00e7eren bu t\u00fcr ila\u00e7lar rahatl\u0131kla kullan\u0131labilir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n A\u015f\u0131 oldu\u011fum g\u00fcn kan suland\u0131r\u0131c\u0131 kullanmal\u0131 m\u0131y\u0131m?<\/span>\n <\/div>\n
    \n

    COVID-19 a\u015f\u0131lar\u0131ndan sonra kan suland\u0131r\u0131c\u0131 kullanmaya gerek yoktur. \u00dclkemizde hen\u00fcz kullan\u0131mda olmayan viral vekt\u00f6r teknolojisi ile \u00fcretilen a\u015f\u0131lardan sonra kan p\u0131ht\u0131la\u015fmas\u0131nda art\u0131\u015f oldu\u011funa ili\u015fkin bildirimler olmakla birlikte bunun a\u015f\u0131dan kaynakland\u0131\u011f\u0131 kesin de\u011fildir ve kan suland\u0131r\u0131c\u0131 kullanmayla engellendi\u011fi g\u00f6sterilememi\u015ftir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Antibiyotik kullan\u0131rken a\u015f\u0131 olabilir miyim?<\/span>\n <\/div>\n
    \n

    Antibiyotik kullan\u0131rken COVID-19 a\u015f\u0131s\u0131 olunabilir. Ancak v\u00fccutta ate\u015fle seyreden bir infeksiyon varken a\u015f\u0131 uyguland\u0131\u011f\u0131nda a\u015f\u0131ya kar\u015f\u0131 yan\u0131t azalabilir. Bu nedenle ate\u015fli hastal\u0131k ge\u00e7irmekte olan ki\u015filerin 48 saat ate\u015fsiz olduktan sonra, \u015fikayetleri azal\u0131nca a\u015f\u0131 olmalar\u0131 \u00f6nerilir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n A\u015f\u0131 oldu\u011fum g\u00fcn sigara i\u00e7ebilir miyim? <\/span>\n <\/div>\n
    \n

    Sigara i\u00e7enlerde baz\u0131 a\u015f\u0131lara kar\u015f\u0131 yan\u0131t\u0131n azald\u0131\u011f\u0131n\u0131 g\u00f6steren veriler bulunsa da a\u015f\u0131 olunan g\u00fcnde sigara i\u00e7ilmesi a\u015f\u0131ya kar\u015f\u0131 yan\u0131t\u0131 ayr\u0131ca etkilemez.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n A\u015f\u0131 oldu\u011fum g\u00fcn alkol kullanabilir miyim?<\/span>\n <\/div>\n
    \n

    A\u015f\u0131 olunan g\u00fcn t\u00fcketilen az-orta miktarda alkol a\u015f\u0131ya kar\u015f\u0131 yan\u0131t\u0131 etkilemez. A\u015f\u0131r\u0131 alkol t\u00fcketiminin ise yan\u0131t\u0131 azaltabilece\u011fi unutulmamal\u0131d\u0131r. Ayr\u0131ca a\u015f\u0131r\u0131 alkol t\u00fcketimine ba\u011fl\u0131 yan etkiler a\u015f\u0131 yan etkileriyle kar\u0131\u015fabilece\u011finden a\u015f\u0131 oldu\u011funuz g\u00fcn y\u00fcksek miktarda alkol t\u00fcketiminden ka\u00e7\u0131nman\u0131z \u00f6nerilir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n A\u015f\u0131 oldu\u011fum g\u00fcn banyo yapabilir miyim?<\/span>\n <\/div>\n
    \n

    A\u015f\u0131 oldu\u011funuz g\u00fcn du\u015f alman\u0131z\u0131n, banyo yapman\u0131z\u0131n hi\u00e7bir sak\u0131ncas\u0131 yoktur.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Kalp pili olanlar hangi a\u015f\u0131y\u0131 olsunlar?<\/span>\n <\/div>\n
    \n

    Kalp pili olan veya kalpte ritim bozuklu\u011fu olan ki\u015filer her iki a\u015f\u0131y\u0131 (Sinovac\u00ae veya BioNTech\u00ae) da olabilirler.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n BioNTech\u00ae a\u015f\u0131s\u0131 kalp kas\u0131 iltihab\u0131 yap\u0131yor mu?<\/span>\n <\/div>\n
    \n

    \u00dclkemizden hen\u00fcz b\u00f6yle bir bildirim olmam\u0131\u015ft\u0131r. Ancak ABD\u2019den veriler BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n uyguland\u0131\u011f\u0131 25 ya\u015f alt\u0131 grupta kalp kas\u0131 iltihab\u0131 g\u00f6r\u00fclme s\u0131kl\u0131\u011f\u0131n\u0131n ayn\u0131 ya\u015f grubunda beklenen s\u0131kl\u0131ktan fazla oldu\u011funu g\u00f6stermektedir. Bununla birlikte Amerikan Kardiyoloji Derne\u011fi bu art\u0131\u015f\u0131n s\u0131n\u0131rl\u0131 oldu\u011funu, hastalar\u0131n iyi seyretti\u011fini ve do\u011frudan a\u015f\u0131ya hen\u00fcz ba\u011flanamad\u0131\u011f\u0131n\u0131 belirtmektedir. Amerikan Hastal\u0131k \u00d6nleme Merkezi (CDC) bu verileri de\u011ferlendirerek 12 ya\u015f \u00fcst\u00fcne BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n yap\u0131lmas\u0131na devam etme karar\u0131 alm\u0131\u015ft\u0131r.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n BioNTech\u00ae a\u015f\u0131s\u0131 genetik yap\u0131m\u0131z\u0131 bozar m\u0131?<\/span>\n <\/div>\n
    \n

    \u0130nsan h\u00fccrelerinde genler h\u00fccre \u00e7ekirde\u011finde bulunur ve DNA yap\u0131s\u0131nda bilgilerden olu\u015fur. BioNTech\u00ae ve benzer teknolojili a\u015f\u0131larda bulunan genetik \u015fifre bile\u015feni (mRNA) ba\u011f\u0131\u015f\u0131kl\u0131k sistemini uyaran proteinlerin h\u00fccrelerimizde sentezlenmesini sa\u011flarlar. Ancak bu \u015fifre (mRNA) h\u00fccre \u00e7ekirde\u011fine giremez, genlerimize ula\u015famaz, genlerimizi de\u011fi\u015ftiremez. 2008 y\u0131l\u0131ndan beri insanlarda kansere ve ba\u015fka infeksiyonlara kar\u015f\u0131 a\u015f\u0131 geli\u015ftirilmesi i\u00e7in denenmekte olan bu teknoloji g\u00fcvenlidir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Sinovac\u00ae a\u015f\u0131s\u0131 fel\u00e7 yap\u0131yor mu?<\/span>\n <\/div>\n
    \n

    Halk aras\u0131nda fel\u00e7 olarak bilinen durum \u00e7e\u015fitli bakteri ve vir\u00fcs infeksiyonlar\u0131ndan sonra g\u00f6r\u00fclen ve beyinle ilgili olmay\u0131p kaslara giden sinirlerdeki hasardan kaynaklanan bir hastal\u0131kt\u0131r ve Guillain-Barre Sendromu olarak tan\u0131mlan\u0131r. Grip a\u015f\u0131lar\u0131nda da g\u00fcndeme gelen bu nadir sendrom a\u015f\u0131lanmayan topluluklarda a\u015f\u0131lanm\u0131\u015f topluluklara k\u0131yasla daha s\u0131k g\u00f6r\u00fclmektedir. Sinovac\u00ae a\u015f\u0131s\u0131 bu a\u00e7\u0131dan g\u00fcvenlidir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n \u00dc\u00e7\u00fcnc\u00fc doz a\u015f\u0131 karar\u0131n\u0131 vermek i\u00e7in antikorlar\u0131ma bakt\u0131rmal\u0131 m\u0131y\u0131m?<\/span>\n <\/div>\n
    \n

    Hay\u0131r. Mevcut antikor testleri ile belirlenen seviyelerin hangi de\u011ferden itibaren ve ne kadar s\u00fcre koruyucu oldu\u011fu bilinememektedir. Ayr\u0131ca testlerden kaynaklanan nedenlerle yalanc\u0131 olarak pozitif sonu\u00e7 da \u00e7\u0131kabilmektedir. Bu nedenle a\u015f\u0131 olmak veya olmamak karar\u0131 i\u00e7in antikorlar\u0131n\u0131za bakt\u0131rman\u0131za gerek yoktur.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n \u0130ki doz BioNTech\u00ae a\u015f\u0131s\u0131 oldum. Ne zaman 3. doz a\u015f\u0131y\u0131 olmal\u0131y\u0131m?<\/span>\n <\/div>\n
    \n

    \u015eimdiki veriler BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n olu\u015fturdu\u011fu ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131n g\u00fc\u00e7l\u00fc bir \u015fekilde 9-12 ay devam etti\u011fini g\u00f6sterdi\u011finden 2 doz BioNTech\u00ae olan ki\u015filerin 9-12 ay boyunca ek doz a\u015f\u0131 olmalar\u0131na gerek yoktur. Bu ki\u015filerde 3. doz a\u015f\u0131ya ihtiya\u00e7 olup olmayaca\u011f\u0131 ve ne zaman olaca\u011f\u0131 bu konuda yap\u0131lmakta olan \u00e7al\u0131\u015fmalar\u0131n sonu\u00e7lar\u0131na ve ortaya \u00e7\u0131kabilecek yeni varyantlara g\u00f6re belli olacakt\u0131r. Sadece BioNTech\u00ae bulunan \u00fclkelerde 2 doz uygulanmaktad\u0131r.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n \u0130ki doz Sinovac\u00ae a\u015f\u0131s\u0131 oldum. Ne zaman 3. doz a\u015f\u0131y\u0131 olmal\u0131y\u0131m? Hangi a\u015f\u0131y\u0131 olmal\u0131y\u0131m?<\/span>\n <\/div>\n
    \n

    \u0130ki doz Sinovac\u00ae a\u015f\u0131s\u0131 olan ki\u015filerde olu\u015fan ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131n 3-6 ay i\u00e7erisinde giderek azald\u0131\u011f\u0131 g\u00f6zlenmektedir. Ayr\u0131ca Sinovac\u00ae a\u015f\u0131s\u0131n\u0131n t\u00fcm d\u00fcnyada birka\u00e7 ay i\u00e7inde hakim hale gelmesi beklenen Delta varyant\u0131na kar\u015f\u0131 etkisi de s\u0131n\u0131rl\u0131 g\u00f6z\u00fckmektedir. Bu nedenlerle iki doz Sinovac\u00ae a\u015f\u0131s\u0131 olanlar\u0131n ikinci dozdan 3-6 ay sonra 3. doz (hat\u0131rlatma veya rapel) a\u015f\u0131y\u0131 olmas\u0131 hem kendilerinin korunmas\u0131 hem de Delta varyant\u0131n\u0131n yay\u0131lmas\u0131n\u0131n \u00f6nlenmesi a\u00e7\u0131s\u0131ndan ak\u0131lc\u0131 olacakt\u0131r.<\/p>\n

    Bu ki\u015filerde 3. doz a\u015f\u0131 Sinovac\u00ae ile uygulanabilir. Ancak Delta varyant\u0131na kar\u015f\u0131 koruyuculu\u011fu sa\u011flamak a\u00e7\u0131s\u0131ndan, \u00f6zellikle sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131, kalabal\u0131k yerlerde \u00e7al\u0131\u015fanlar gibi vir\u00fcsle kar\u015f\u0131la\u015fma olas\u0131l\u0131\u011f\u0131 y\u00fcksek ki\u015filerin, ayr\u0131ca daha g\u00fc\u00e7l\u00fc ba\u011f\u0131\u015f\u0131kl\u0131k olu\u015fturdu\u011fu i\u00e7in ileri ya\u015ftaki ki\u015filer ve ba\u011f\u0131\u015f\u0131kl\u0131k yetmezli\u011fi olanlar\u0131n 3. doz a\u015f\u0131y\u0131 BioNTech\u00ae ile olmas\u0131 tercih edilmelidir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n BioNTech\u00ae a\u015f\u0131s\u0131 ileri ya\u015ftaki ki\u015filerde daha \u00e7ok yan etki yap\u0131yor mu?<\/span>\n <\/div>\n
    \n

    BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n yan etkileri ya\u015f ilerledik\u00e7e azalmakta buna kar\u015f\u0131n koruyuculu\u011funda ise \u00f6nemli bir de\u011fi\u015fiklik olmamaktad\u0131r. Sinovac\u00ae a\u015f\u0131s\u0131n\u0131n koruyuculu\u011fu ileri ya\u015ftaki ki\u015filerde azald\u0131\u011f\u0131ndan ileri ya\u015f grubunda \u00fclkemizdeki a\u015f\u0131lardan BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n uygulanmas\u0131 \u00f6nerilir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Hastal\u0131\u011f\u0131 ge\u00e7irmi\u015f olan ki\u015filerin a\u015f\u0131lanmas\u0131 gerekli mi? Ne zaman a\u015f\u0131lans\u0131nlar?<\/span>\n <\/div>\n
    \n

    Bug\u00fcne kadarki bilimsel veriler hastal\u0131\u011f\u0131 belirtili olarak ge\u00e7iren ki\u015filerde ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131n yakla\u015f\u0131k 6-12 ay devam etti\u011fini g\u00f6stermekle birlikte zamanla koruyuculu\u011fun azalmas\u0131 s\u00f6z konusu oldu\u011fundan hastal\u0131\u011f\u0131 ge\u00e7iren ki\u015filerin\u00a03-6\u00a0aydan itibaren a\u015f\u0131lanabilecekleri d\u00fc\u015f\u00fcn\u00fclmektedir<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Hastal\u0131\u011f\u0131 ge\u00e7irmi\u015f olanlar hangi a\u015f\u0131yla a\u015f\u0131lans\u0131nlar?<\/span>\n <\/div>\n
    \n

    Hastal\u0131\u011f\u0131 ge\u00e7irmi\u015f olan ki\u015filere 3-6. aydan itibaren tek doz BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n uygulanmas\u0131 ile y\u00fcksek d\u00fczeyde ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 olu\u015ftu\u011funu g\u00f6steren \u00e7al\u0131\u015fmalar bulunmaktad\u0131r. Daha az say\u0131da veri olmakla birlikte hastal\u0131\u011f\u0131 ge\u00e7irmi\u015f olan ki\u015filere iki doz olmak kayd\u0131yla Sinovac\u00ae a\u015f\u0131s\u0131 uygulamas\u0131n\u0131n da y\u00fcksek d\u00fczeyde ba\u011f\u0131\u015f\u0131kl\u0131k sa\u011flad\u0131\u011f\u0131 g\u00f6sterilmi\u015ftir. Bu konuda kesin \u00f6neride bulunmak i\u00e7in hastal\u0131\u011f\u0131 ge\u00e7irenlere tek doz BioNTech\u00ae veya iki doz Sinovac\u00ae uygulamalar\u0131ndan hangisinin daha faydal\u0131 olaca\u011f\u0131n\u0131 ara\u015ft\u0131ran \u00e7al\u0131\u015fma sonu\u00e7lar\u0131na ihtiya\u00e7 vard\u0131r. Ancak eldeki verilerle Delta varyant\u0131n\u0131n yay\u0131lmas\u0131n\u0131n \u00f6nlenmesi ve yeni varyantlar\u0131n ortaya \u00e7\u0131kmas\u0131n\u0131n engellenebilmesi i\u00e7in hastal\u0131\u011f\u0131 ge\u00e7irenlere 3-6 ay sonra BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n uygulanmas\u0131 daha ak\u0131lc\u0131 g\u00f6r\u00fcnmektedir.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n \u0130ki doz a\u015f\u0131dan sonra COVID ge\u00e7irdim. \u00dc\u00e7\u00fcnc\u00fc doz a\u015f\u0131m\u0131 ne zaman olmal\u0131y\u0131m?<\/span>\n <\/div>\n
    \n

    Bir veya iki doz sonras\u0131nda COVID ge\u00e7iren ki\u015filer t\u0131pk\u0131 a\u015f\u0131lanmam\u0131\u015f ve COVID ge\u00e7irmi\u015f ki\u015filer gibi hastal\u0131ktan sonra 3-6. aydan itibaren a\u015f\u0131lanabilecekleri d\u00fc\u015f\u00fcn\u00fclmektedir. Bir doz Sinovac\u00ae a\u015f\u0131s\u0131ndan sonra COVID ge\u00e7irmi\u015f olanlar\u0131n 3-6. aydan itibaren olacaklar\u0131 a\u015f\u0131 birinci dozla ayn\u0131 a\u015f\u0131 olabilece\u011fi gibi hem kendilerinin korunmas\u0131 hem de Delta varyant\u0131n\u0131n yay\u0131lmas\u0131n\u0131n \u00f6nlenmesi ve yeni varyantlar\u0131n ortaya \u00e7\u0131kmas\u0131n\u0131n engellenebilmesi a\u00e7\u0131s\u0131ndan BioNTech\u00ae a\u015f\u0131s\u0131 olmalar\u0131 do\u011fru olacakt\u0131r.<\/p>\n <\/div>\n \n

    \n \n <\/i><\/span>\n <\/i><\/span>\n <\/span>\n Solid organ nakli uygulanm\u0131\u015f ki\u015filere COVID-19 a\u015f\u0131s\u0131 yap\u0131labilir mi?<\/span>\n <\/div>\n
    \n

    Solid organ nakli yap\u0131lm\u0131\u015f ki\u015filerde COVID-19\u2019un a\u011f\u0131r seyretme riski y\u00fcksektir, bu nedenle a\u015f\u0131lanarak hastal\u0131ktan korunmalar\u0131 olduk\u00e7a \u00f6nemlidir. T\u00fcm solid organ nakli al\u0131c\u0131lar\u0131nda, \u00fclkemizde olan inaktive virus a\u015f\u0131s\u0131 veya mRNA a\u015f\u0131s\u0131 uygulanabilmektedir. Ancak bu ki\u015filer ba\u011f\u0131\u015f\u0131kl\u0131k sistemlerini zay\u0131flatan ila\u00e7lar da kulland\u0131klar\u0131 i\u00e7in, daha immunojen olan mRNA a\u015f\u0131lar\u0131n\u0131 tercih etmeleri \u00f6nerilir. Ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 etkileyen ila\u00e7lar\u0131n kullan\u0131m\u0131 bu ki\u015filerde ayn\u0131 zamanda a\u015f\u0131ya yan\u0131t ve koruyuculuk oranlar\u0131n\u0131n da d\u00fc\u015f\u00fckl\u00fc\u011f\u00fcne neden olabilece\u011finden, solid organ nakli al\u0131c\u0131lar\u0131 a\u015f\u0131land\u0131ktan sonra maske ve mesafe gibi ki\u015fisel koruyucu \u00f6nlemlere uymaya da devam etmelidir. Transplantasyondan sonra a\u015f\u0131lama i\u00e7in ideal zaman tam olarak bilinmemekle birlikte, hastal\u0131\u011f\u0131 edinme riskine ve koruyucu ba\u011f\u0131\u015f\u0131k yan\u0131t geli\u015ftirebilme olas\u0131l\u0131\u011f\u0131na g\u00f6re de\u011ferlendirme yap\u0131lmal\u0131d\u0131r. M\u00fcmk\u00fcn olan durumlarda, transplantasyondan sonra en erken 1. ayda, T veya B lenfositleri azaltan tedaviler (\u00f6rn. anti-timosit glob\u00fclin, rituksimab vb.) alan ki\u015filerde ise bu ajanlar\u0131n kullan\u0131m\u0131ndan en az 3 ay sonra a\u015f\u0131lama yap\u0131lmas\u0131 tercih edilmelidir.<\/p>\n <\/div>\n <\/div>\n\n\n\n <\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":4553,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[5],"tags":[],"_links":{"self":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/4545"}],"collection":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/comments?post=4545"}],"version-history":[{"count":5,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/4545\/revisions"}],"predecessor-version":[{"id":4568,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/4545\/revisions\/4568"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media\/4553"}],"wp:attachment":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media?parent=4545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/categories?post=4545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/tags?post=4545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}